Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma

2012 ◽  
Vol 24 (6) ◽  
pp. 640-645 ◽  
Author(s):  
Jong Yeon Kim ◽  
June Sung Lee ◽  
Dong-Hoon Oh ◽  
Yun Hyuk Yim ◽  
Hyo Keun Lee
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Benefit ◽  
Transcatheter Arterial Chemoembolization ◽  
Ruptured Hepatocellular Carcinoma ◽  
Arterial Chemoembolization

scholarly journals Imaging features and outcomes in patients with ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization: a retrospective clinical study

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110077
Author(s):  
Wenpeng Zhao ◽  
Xiaopu Hou ◽  
Honglu Li ◽  
Jiang Guo ◽  
Liang Cai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Embolization ◽  
Type I ◽  
Imaging Features ◽  
Resonance Imaging ◽  
Type Iii ◽  
Retrospective Clinical Study ◽  
Ruptured Hepatocellular Carcinoma ◽  
Arterial Chemoembolization

Objective To summarize and analyze the imaging features and outcomes of patients with ruptured hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TACE). Methods We investigated all consecutive patients with HCC who received standardized TACE based on our hospital database. Ruptured HCCs were divided into three types according to their relationship with the liver capsule, determined by computed tomography or magnetic resonance imaging scans: Type I, portion of tumor cambered outwards ≤30%; Type II, portion of tumor cambered outwards >30% and <50%; and Type III, portion of tumor cambered outwards ≥50%. Results There were 54, 40, and 26 patients with Type I, II, and III HCCs, respectively. Among these, eight patients developed ruptured tumors within 2 weeks after TACE, including one, two, and five patients with type I, II, and III ruptured HCCs, respectively. Patients with type III HCCs had a shorter median survival time than patients with type I–II HCCs. Conclusions Patients with type III HCCs might have a higher re-rupture rate and benefit less from emergency arterial embolization procedures than patients with type I–II HCCs.

scholarly journals A Case of Ruptured Hepatocellular Carcinoma Immediately after Transcatheter Arterial Chemoembolization

2015 ◽  
Vol 64 (1) ◽  
pp. 35-40
Author(s):  
Yumi FUKUI ◽  
Issei SAEKI ◽  
Tadasuke HANAZONO ◽  
Norikazu TANABE ◽  
Yohei URATA ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Ruptured Hepatocellular Carcinoma ◽  
Arterial Chemoembolization

scholarly journals Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Lei Liang ◽  
Chao Li ◽  
Ming-Da Wang ◽  
Hong Wang ◽  
Ya-Hao Zhou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Benefit ◽  
Large Scale ◽  
Prediction Models ◽  
Transcatheter Arterial Chemoembolization ◽  
Survival Prediction ◽  
Net Survival ◽  
Online Calculator ◽  
Survival Predictors ◽  
Arterial Chemoembolization

Abstract Background and aims Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC. Methods From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE. Results A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE. Conclusions Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE.

Sign in / Sign up

Export Citation Format

Share Document